LXRX
Lexicon Pharmaceuticals Inc
1.70$
-4.5%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 80.8% | 77.0% | 87.4% | 85.9% | 83.6% | 82.5% | 82.6% | 64.3% | 59.5% | 55.1% | 69.2% | 78.6% | |
| 7.6% | 9.8% | 23.1% | 9.5% | 10.8% | 22.3% | 21.1% | 9.5% | 24.1% | 18.6% | 14.2% | 16.4% | |
| 79.0% | 74.1% | 85.2% | 83.0% | 80.5% | 79.7% | 65.5% | 61.6% | 56.3% | 52.0% | 63.5% | 76.2% | |
| 0.1% | 0.4% | 0.4% | 0.7% | 0.9% | 1.2% | 15.9% | 1.0% | 1.1% | 1.3% | 4.4% | 0.7% | |
| 0.1% | 0.2% | 0.1% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% | 0.1% | 0.2% | 0.1% | 0.5% | |
| 16.1% | 19.4% | 10.7% | 11.9% | 13.9% | 14.9% | 15.0% | 19.7% | 21.6% | 24.1% | 16.6% | 17.8% | |
| 49.5% | 59.4% | 30.8% | 35.7% | 44.4% | 51.1% | 58.7% | 42.6% | 41.6% | 41.9% | 24.5% | 30.2% | |
| 11.7% | 13.7% | 5.6% | 7.5% | 11.2% | 15.2% | 37.2% | 15.4% | 10.5% | 11.3% | 3.7% | 5.9% | |
| 0.5% | 0.6% | 0.3% | 0.3% | 0.4% | 0.4% | 14.5% | 0.4% | 0.8% | 3.4% | 0.6% | 0.7% | |
| 4.4% | 6.3% | 1.9% | 3.3% | 4.4% | 5.0% | 3.6% | 2.6% | 1.8% | 1.7% | 1.1% | 0.9% | |
| 35.9% | 43.4% | 23.9% | 26.6% | 31.1% | 33.6% | 19.7% | 24.9% | 27.4% | 26.7% | 18.5% | 20.6% | |
| 50.5% | 40.6% | 69.2% | 64.3% | 55.6% | 48.9% | 41.3% | 57.4% | 58.4% | 58.1% | 75.5% | 69.8% | |
| -621.1% | -770.1% | -435.1% | -500.5% | -602.1% | -659.2% | -669.4% | -881.8% | -972.2% | -1,090.7% | -750.9% | -820.0% | |
| 88.6% | 106.8% | 58.8% | 83.3% | 112.6% | 121.1% | 121.6% | 161.2% | 176.5% | 196.5% | 148.9% | 175.0% |
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.